Musculoskeletal Outcomes of Glucagon-Like Peptide-1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults - PubMed
4 hours ago
- #obesity
- #GLP-1 receptor agonists
- #musculoskeletal outcomes
- GLP-1 receptor agonists (GLP-1 RAs) are associated with lower risks of osteoporosis, major osteoporotic fractures, cervical and thoracolumbar disc disorders, and osteoarthritis compared to other obesity medications in nondiabetic adults aged 50 and above.
- The study used a retrospective cohort design with data from TriNetX, involving 18,062 propensity score-matched participants.
- Relative risks (RR) were significantly reduced: osteoporosis (RR 0.48), fractures (RR 0.15), cervical disc degeneration (RR 0.34), thoracolumbar disc disease (RR 0.36), and osteoarthritis (RR 0.45).
- Protective effects of GLP-1 RAs were consistent across age, sex, BMI, and drug subtypes, and remained robust in sensitivity analyses.
- The number needed to treat (NNT) ranged from 9 for osteoarthritis to 88 for major osteoporotic fractures, indicating favorable clinical benefits.